Biocryst Pharmaceuticals (BCRX) Cash & Current Investments (2010 - 2026)

Biocryst Pharmaceuticals has reported Cash & Current Investments for 17 years, with the latest figure at $238.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 25.35% year-over-year to $238.4 million; the trailing twelve-month figure through Mar 2026 stood at $238.4 million (up 25.35% YoY), and the FY2025 full-year result was $274.7 million, down 14.37% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $238.4 million, down from $274.7 million in the prior quarter.
• The five-year high for Cash & Current Investments was $426.9 million in Q3 2022, with the low at $51.3 million in Q1 2022.
• Historically, Cash & Current Investments has averaged $271.3 million across 5 years, with a median of $274.7 million in 2025.
• The largest YoY upside for Cash & Current Investments was 1074.45% in 2022 against a maximum downside of 76.16% in 2022.
• Biocryst Pharmaceuticals' Cash & Current Investments stood at $121.0 million in 2022, then jumped by 221.44% to $389.0 million in 2023, then slipped by 17.52% to $320.8 million in 2024, then decreased by 14.37% to $274.7 million in 2025, then retreated by 13.23% to $238.4 million in 2026.
• The last three Cash & Current Investments figures came in at $238.4 million (Q1 2026), $274.7 million (Q4 2025), and $212.9 million (Q3 2025), per Business Quant data.